![](https://endpts.com/wp-content/uploads/2021/02/Andrew-Crockett-KalVista-tile-scaled.jpg)
Andrew Crockett, KalVista CEO
Five months after getting slapped with a clinical hold, KalVista gets the OK to restart oral HAE program
KalVista’s oral program for the prevention of hereditary angioedema (HAE) was only on hold for five months — but that was enough time for rival Pharvaris …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.